MicroRNA 26a-1 (miR-26a-1)

MicroRNA 26a-1 is a highly conserved small non-coding RNA (miRNA) belonging to the miR-26 precursor family, encoded on human chromosome 3. It is processed into a mature miRNA of 21–22 nucleotides, with a critical seed region that binds target mRNAs and regulates their translation or stability. miR-26a-1 acts as a post-transcriptional regulator of gene expression, targeting multiple genes involved in cell cycle control (e.g., cyclin D2, cyclin E2), cell proliferation, apoptosis, and differentiation. It functions as a tumor suppressor in diverse cancers, and is known to negatively regulate oncogenic proteins such as EZH2 (especially in chronic lymphocytic leukemia), SMAD-1 and SMAD-4 (key mediators in TGF-β/BMP signaling), and ANXA1 in lung cancer. In vascular biology, miR-26a-1 modulates the differentiation, migration, and apoptosis of smooth muscle cells. Clinically, loss or reduction of MIR26A1 is associated with tumorigenesis and poor prognosis in several cancers, and therapeutic efforts to restore its function (e.g., via miRNA mimics or epigenetic drugs like decitabine) are under investigation. MicroRNA modulation is complex due to the large number of direct and indirect targets, making targeted therapeutic strategies challenging and associated with risk of unintended effects.

Other names

MIR26A1hsa-mir-26a-1MIR26AMIRN26A1mir-26a-1MIR26A-1hsa-miR-26a-1

Epigenetic modulation: Decitabine induces expression of MIR26A1 and thus downregulates oncogenic EZH2. Gene silencing/miRNA mimic delivery: Therapeutic delivery of miR-26a inhibits cancer cell formation, induces tumor-specific apoptosis, and regulates cell cycle. AntagomiR inhibition: miRNA-26a antagomiR (inhibitor) used to modulate SMC marker expression and differentiation.